We need to focus on the opportunities that this offers surgeons. Partial Knee Replacement adoption only truly scales when confidence replaces hesitation. OSSTEC's streamlined surgical technique enables this. Contact us to find out how this can make a difference to your surgical offering.

When appropriate, partial knee preserves more of the patient’s natural anatomy, enabling faster recovery, more normal movement and a quicker return to activity. This means that patients can get back to doing what they love, faster. What do patients love about partial knee replacement? In this video, our faculty and partners share where partial knee fits in practice, the real world benefits they’re seeing and why it continues to earn its place alongside total knee.

Dr. Scott will be attending the BASK Annual Meeting in Glasgow (14–15 April). If you're heading there too, it’s a great chance to connect, talk all things orthopaedics, and explore how design and surgery come together to drive better outcomes.

The team at OSSTEC are back from American Academy of Orthopaedic Surgeons (AAOS) - and still catching up on everything that happened! A packed few days, from hosting and running surgical labs to capturing the moments in between. The kind of environment where everything moves quickly, but the conversations and connections stick. A big thank you to everyone who came by, spent time with us, and got involved. And to our colleagues and partners - always good to be on the ground t

Dr. Nick Pachuda has been appointed to the Board and Christopher Campbell has been appointed as US Commercial Lead to establishment of US operations. These two appointments strengthen the company's leadership ahead of commercial launch.

Come join us at our Surgeon Labs Tuesday to Thursday – RSVP here to let us know if you’re coming! https://bit.ly/3ZSWD2p

OSSTEC kicked off 2025 with a strong start, successfully closing its investment round to fund regulatory approval and market launch, 
while also expanding the team to.

OSSTEC closed 2024 on a high note with a successful cadaver lab at HSS in New York. The world-renowned surgeons on our clinical advisory board provided invaluable feedback to refine OSSTEC implants and surgical instruments.

As 2024 kicks off, we’re taking a moment to reflect on an incredible journey in 2023. Last year was marked by hashtag#growth , hashtag#innovation and laying the foundations for future hashtag#impact : Closed our investment round: Our oversubscribed investment round totalled £2M, combining support from Parkwalk , SFC Capital , Oxford Innovation and Innovate UK Grew our team to 8 people: The amazing OSSTEC team combines experience from previous founders, surgeons, orth

OSSTEC had an amazing time exhibiting at International Society for Technology in Arthroplasty (ISTA), New York, in September. It was a pleasure to unveil our first product to surgeons and industry. Some key highlights include podium presentations from our team demonstrating research at OSSTEC and surgical usability sessions trialling our devices.

We're thrilled to share that OSSTEC has been nominated for Best SEIS Investee Company of 2023! This recognition highlights our team's dedication to delivering impact and innovation in hashtag#medtech . We're honoured to be acknowledged among the best in the S/EIS community. Our CEO, Maxwell Munford, PhD , has also been nominated for hashtag#Entrepreneur of the Year! Special thanks to our amazing team, partners and investors for their support. Stay tuned as we eagerly

OSSTEC is honored to announce nominations for three prestigious awards by the UK Business Angels Association and EISA. Our gratitude extends to the Royal Academy of Engineering and Innovate UK for their sponsorship. These nominations underscore our team's dedication to technological innovation.

OSSTEC successfully closes an oversubscribed £1.2M funding round, bolstering our journey from lab to operating room with our 3D printing and biomimetic implants. This boost empowers team growth and tech development. Immense gratitude to our investors and supporters, including SFC, Parkwalk Advisors, and Embryo Ventures.